Company Analysis

Ligand Pharmaceuticals Incorporated (LGND)

Nasdaq: LGND · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 1994
Grade6.3
◀ Past 5.7● Present 6.9▶ Future 6.0

Who runs Ligand Pharmaceuticals Incorporated

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Davis Todd C
Chief Executive Officer. First filing Mar 2007, latest Jul 6, 2026, 8 filings in all.
Officers reporting now
3
of 10 people with a filing in the last fifteen months
Directors reporting now
7
18 people on the record since 2006
Officerssales are open-market, Nov 12, 2025 to Nov 12, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Reardon AndrewCLO & SecretaryNov 2022Nov 4, 202673 · $11.9M
Espinoza OctavioChief Financial OfficerNov 2022Aug 14, 202614 · $13.0M
Davis Todd CChief Executive OfficerMar 2007Jul 6, 2026none
Directorssales are open-market, Nov 12, 2025 to Nov 12, 2026
NameRoleFirst filingLatest filingSales, 12 months
Aryeh JasondirectorSep 2006Nov 12, 202615 · $3.0M
Zimmermann MartinedirectorSep 2023Sep 24, 20261 · $300,000
Haas JasondirectorJun 2022Aug 14, 20263 · $3.7M
Sabba Stephen LdirectorAug 2008Jun 18, 20263 · $1.2M
Lamattina John LdirectorFeb 2011Jun 12, 20265 · $1.6M
Gray Nancy RyandirectorAug 2017Jun 9, 2026none
Kozarich John WdirectorJan 2006Jun 9, 202635 · $1.0M
Earlier names on the record10, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton LGND · research, not advice